Has Bayo Curry-Winchell, MD received payments from drug or device companies?

Yes. Drug and device makers reported $74,087 in general payments to Bayo Curry-Winchell, MD across 17 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bayo Curry-Winchell, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bayo Curry-Winchell, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bayo Curry-Winchell, MD

Family Medicine · Reno, NVNPI 1770652448

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $58,748 of the $74,087 with a category attached, or 79.3%. GSK accounts for 70.9% of it on its own, with 5 other manufacturers making up the rest. Among family medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$74,087in general payments, 2019–2025

Across 17 payments — averaging $4358.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$53K
Withings, Inc.$12K
Teva Pharmaceuticals USA, Inc.$8K
GE HealthCare$729
Seqirus USA Inc$170
Cepheid$68

What the payments were for

Consulting fees$58,74879%
Speaking & faculty fees$12,46817%
Travel & lodging$2,4383%
Food & beverage$4331%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	6	$52,500
Withings, Inc.	1	$12,400
Teva Pharmaceuticals USA, Inc.	6	$8,220
GE HealthCare	2	$729
Seqirus USA Inc	1	$170
Cepheid	1	$68

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SHINGRIX$52,500
Fluad Quadrivalent$170
FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL)$170

How this compares

$74,087 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada →

Medicare billing

Part B allowed, 2024

$6,237

Medicare patients

Services billed

103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ipratropium Bromide	11	$68

Paid to pharmacies, not to this prescriber.

Other family medicine in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →